Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
Hematology
•
Pediatric Hematology
•
Benign Hematology
•
Thalassemia
How do you counsel patients with transfusion dependent beta thalassemia about luspatercept?
Related Questions
What would your next line of treatment be for a patient with Hb SC with history of recurrent VOC and new bone infarct who is already on hydroxyurea and phlebotomy?
Is it true that a ferritin above 200 essentially rules out iron deficiency?
What additional testing is recommended with heterozygous HFE C282Y mutation whose ferritin is elevated and transferrin saturation percentage is at baseline?
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
Are SCDs contraindicated in patients with acute DVTs?
What subset of sickle cell disease patients are you offering sickle cell disease gene therapy?
For patients with incidental findings of venous thromboembolism during workup of a treatable malignancy, how do you approach discontinuation after the treatment is complete?
Are there any circumstances where you would consider bridging for patients on DOACs?
How do you manage hyperalgesia in patients with sickle cell disease?
Would you anticoagulate a patient with splenic infarctions in the setting of CMV viremia?
